Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
Extension without change of a currently approved collection
No
Regular
03/27/2026
Requested
Previously Approved
36 Months From Approved
04/30/2026
17,191
17,191
8,960
8,944
0
0
This information collection supports implementation of Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) - which governs pharmacy compounding and outsourcing facilities. The requirements include reporting, recordkeeping, and disclosures.
While we have retained our currently approved burden estimates, we have corrected several inadvertent errors. We added more precision to the number of responses per respondent figures in rows 3 and 6; corrected the average burden per response in row 6 (from 0.2 to 0.025 hour (1.5 mins.)); and corrected the total hours calculation in rows 3, 6, and 7. Due to these corrections, we have adjusted our total burden estimate upward by 16 hours (from 8,944 to 8,960) annually.
$1,513,211
No
Yes
No
No
No
No
No
Anne Taylor 240 402-5683 anne.taylor@fda.hhs.gov
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/27/2026
Something went wrong when downloading this file. If you have any questions, please send an email to risc@gsa.gov.